A complex financing given the amounts involved
A complex financing given the amounts involvedFINANCING ISSUE
The group announced the issuance of a second tranche of bonds to Heights Capital, related to the February 2024 issuance, and amended the bond conditions. Overall, this will not significantly impact our figures, as the additional dilution is at least partially or fully offset by the cash inflow.
FACT
Crossject announced the issuance to Heights of a second tranche with a nominal value of €2,496,400, at an issue price of 90% of the nominal value, equating to €2,246,400. The group also amended the terms and conditions of the OCAs issued on 28 February 2024.
ANALYSIS
Crossject has revised the terms of the first tranche as follows: the maturity date for the OCAs has been extended from 28 February 2027 to 28 December 2027; the bi-monthly amortisation per OCA has been reduced from €6,000 to €4,500, with certain exceptions; OCA holders’ right to request early redemption has been modified, allowing up to two redemption dates without requiring Crossject to pay the final redemption in shares; the conversion price of the OCAs is now the lower of €1.677 or 110% of the market value on the issue date of the new tranche, with a minimum of €1; and the period for conversion price adjustment in the event of securities issuance for a minimum gross amount of €5m has been extended to include 28 February 2027. The new tranche of OCAs, with a nominal amount of €2.246m, is not contingent on FDA/EUA approval.
The conversion price for all OCAs, if converted at the OCA holders’ discretion, is set at €1.677, which is the lower of €1.677 or 110% of the market value on the issue date of the new tranche.
In summary, the potential number of new shares from converting all OCAs ranges from 5,251,905 to 8,807,045. Including the recent capital increase in December 2024, which has been accounted for, the total number of shares could rise from approximately 44 million to a maximum of 55 million. Based on our projections of share price trends, we estimate 50.7 million shares, which does not significantly affect our target price. However, we find these operations and amendments somewhat complex given the limited amounts involved.
IMPACT
Our forecasts remain largely unchanged in light of the news. We will account for a degree of dilution, which will be partially or fully offset by the cash inflow.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.